Should CMS Manage 340B? Sen. Hatch Raises Oversight Concerns With HHS
Finance Committee chair asks HHS' Azar how he will address concerns that 340B program has expanded beyond its original intent and needs reining in.
You may also be interested in...
House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Former CMS acting administrator Andy Slavitt says agency’s direction during Biden administration depends on nominee, but trust fund’s looming insolvency will be ‘an issue you can’t avoid.’ The president’s priorities around health equity, racial justice and mental health will make their way into CMS policy and demonstration models, Slavitt suggests.